Tap to start →
Photo: National Cancer Institute / Unsplash
1 / 3
Lixisenatide is a once-daily GLP-1 receptor agonist for type 2 diabetes, now sold in the US mainly inside Soliqua, a combination pen with insulin glargine.
2 / 3
Lixisenatide was approved in the US in 2016 as Adlyxin, a once-daily injection for type 2 diabetes.
3 / 3
If you see lixisenatide on a pharmacy list, it is almost always part of an insulin combination for diabetes, not a weight-loss option.
Lixisenatide is a once-daily GLP-1 receptor agonist for type 2 diabetes, now sold in the US mainly inside Soliqua, a combination pen with insulin glargine.
Tap below for the full page. Not medical advice; talk to your clinician about your care.